[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
You seem to have javascript disabled. Please note that many of the page functionalities won't work as expected without javascript enabled.
 
 
Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (159)

Search Parameters:
Keywords = larynx cancer

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
11 pages, 423 KiB  
Case Report
Metastasis of Squamous Cell Carcinoma of the Larynx to the Right Adrenal Gland—A Case Report
by Eliza Działach, Michał Simlot, Karolina Osowiecka, Elżbieta Nowara, Jarosław Markowski and Mateusz Grajek
Clin. Pract. 2025, 15(3), 49; https://doi.org/10.3390/clinpract15030049 - 26 Feb 2025
Viewed by 132
Abstract
Background/Objectives: Malignant adrenal tumors comprise both primary adrenal neoplasms and metastatic lesions, with the latter being significantly more common. Squamous cell carcinoma (SCC) of the larynx is a prevalent head and neck cancer that typically spreads to the cervical lymph nodes, with [...] Read more.
Background/Objectives: Malignant adrenal tumors comprise both primary adrenal neoplasms and metastatic lesions, with the latter being significantly more common. Squamous cell carcinoma (SCC) of the larynx is a prevalent head and neck cancer that typically spreads to the cervical lymph nodes, with distant metastases being rare. Among such metastases, adrenal gland involvement is particularly uncommon, presenting unique diagnostic and therapeutic challenges. The study aimed to explore the progression, diagnostic process, and therapeutic management of a rare case of SCC of the larynx metastasizing to the adrenal gland, highlighting the role of advanced diagnostic imaging and a multidisciplinary approach in patient care. Methodology: A 66-year-old male with grade 3 SCC of the larynx underwent total laryngectomy, selective cervical lymphadenectomy, and radiotherapy with a dose of 70 Gy. Chemotherapy was discontinued due to hematological complications. Post-treatment monitoring included CT and PET-CT imaging, leading to the detection of a large adrenal mass. Surgical biopsy confirmed metastatic SCC in the adrenal gland, as resection was not feasible due to extensive invasion. Diagnostic imaging and histopathological examination were complemented by biochemical evaluations to assess hormonal activity. Results: The adrenal mass was identified as a metastasis from the laryngeal SCC. Imaging studies provided detailed insights into the lesion’s size, metabolic activity, and non-functional status. Despite comprehensive efforts, the tumor was deemed unresectable, highlighting the aggressive nature of the disease and the limitations of current therapeutic modalities. Conclusions: This rare case emphasizes the importance of early detection, advanced imaging techniques, and interdisciplinary collaboration in managing complex metastatic presentations. It underscores the critical need for further research into systemic treatments, such as immunotherapy, and the development of standardized protocols for rare metastatic patterns. The study contributes to the growing body of literature on the management of uncommon cancer metastases, advocating for individualized patient care and innovation in treatment strategies. Full article
(This article belongs to the Special Issue Clinical Outcome Research in the Head and Neck)
Show Figures

Figure 1

Figure 1
<p>CT imaging with identified a 7 × 9 cm mass in the right adrenal gland.</p>
Full article ">
13 pages, 1898 KiB  
Systematic Review
Sentinel Node Biopsy in Laryngeal Cancer: A Systematic Review and Meta-Analysis
by Pegah Sahafi, Ramin Sadeghi, Emran Askari, Azadeh Sahebkari, Mitra Ghahraman, Ehsan Khadivi, Kamran Khazaeni, Vahid Reza Dabbagh Kakhki and Sara Harsini
Diagnostics 2025, 15(3), 366; https://doi.org/10.3390/diagnostics15030366 - 4 Feb 2025
Viewed by 510
Abstract
Background: Sentinel lymph node (SLN) biopsy offers a minimally invasive approach to staging lymph node involvement in laryngeal squamous cell carcinoma (SCC). Despite its adoption in other cancers, its accuracy in laryngeal SCC remains under investigation. This systematic review and meta-analysis evaluates the [...] Read more.
Background: Sentinel lymph node (SLN) biopsy offers a minimally invasive approach to staging lymph node involvement in laryngeal squamous cell carcinoma (SCC). Despite its adoption in other cancers, its accuracy in laryngeal SCC remains under investigation. This systematic review and meta-analysis evaluates the diagnostic performance of SLN mapping in laryngeal cancer. Methods: A systematic search of MEDLINE, Scopus, and Google Scholar was conducted using the keywords “(larynx OR laryngeal) AND sentinel”, with no date or language restrictions. Studies reporting SLN detection rates and/or sensitivity in laryngeal SCC were included. A random-effects model was applied for data pooling, and subgroup analyses were performed based on tumor location (supraglottic versus transglottic) and mapping material (radiotracer versus blue dye). Publication bias was assessed using funnel plots and statistical methods. Results: Nineteen studies, encompassing 366 patients, were analyzed. The overall pooled SLN detection rate was 90.8% (95% CI: 86–94.1), and sensitivity was 88% (95% CI: 81–94). Supraglottic tumors demonstrated superior outcomes (detection rate: 93.7%, sensitivity: 96%) compared to transglottic tumors (detection rate: 84.7%, sensitivity: 71%). Radiotracers significantly outperformed blue dye, with detection rates of 90.8% versus 81.5% and sensitivities of 88% versus 77%. Conclusions: SLN mapping is a reliable technique for staging laryngeal SCC, particularly for supraglottic tumors, where high detection rates and sensitivity were observed. Radiotracers offer superior performance compared to blue dye, underscoring their clinical value. These findings support the feasibility and accuracy of SLN biopsy in laryngeal cancer, while emphasizing the importance of tumor location and mapping material. Full article
(This article belongs to the Section Medical Imaging and Theranostics)
Show Figures

Figure 1

Figure 1
<p>PRISMA flow diagram.</p>
Full article ">Figure 2
<p>Forest plot illustrating the pooled detection rate across included studies.</p>
Full article ">Figure 3
<p>Forest plot illustrating the pooled sensitivity across included studies.</p>
Full article ">Figure 4
<p>Funnel plot of detection rate pooling. White circles represent the included studies, and white diamond indicates the pooled detection rate of these studies. Black circles represent the studies trimmed to correct for asymmetry, while the black diamond represents the adjusted pooled effect size accounting for potential publication bias, as calculated using the Duval–Tweedie trim and fill method.</p>
Full article ">Figure 5
<p>Funnel plot of sensitivity pooling. White circles represent the included studies, and white diamond indicates the pooled detection rate of these studies. Black circles indicate the studies trimmed to correct for asymmetry, with the black diamond representing the adjusted pooled effect size accounting for potential publication bias, as calculated using the Duval–Tweedie trim and fill method.</p>
Full article ">
13 pages, 639 KiB  
Systematic Review
Clinical and Pathological Staging Discrepancies in Laryngeal Cancer: A Systematic Review
by Giancarlo Pecorari, Andrea Lorenzi, Matteo Caria, Gian Marco Motatto and Giuseppe Riva
Cancers 2025, 17(3), 455; https://doi.org/10.3390/cancers17030455 - 28 Jan 2025
Viewed by 573
Abstract
Background/Objectives: Laryngeal squamous cell carcinoma (LSCC) is one of the most prevalent and challenging malignancies of the head and neck. Clinical staging (cTNM) plays a pivotal role in therapeutic decision-making. However, current imaging modalities often fall short, resulting in discrepancies between cTNM [...] Read more.
Background/Objectives: Laryngeal squamous cell carcinoma (LSCC) is one of the most prevalent and challenging malignancies of the head and neck. Clinical staging (cTNM) plays a pivotal role in therapeutic decision-making. However, current imaging modalities often fall short, resulting in discrepancies between cTNM and pathological staging (pTNM). This systematic review aimed to critically evaluate the existing literature on the concordance between clinical and pathological staging of LSCC, quantifying staging inaccuracies and highlighting the prevalence of both under- and overstaging at diagnosis. Methods: A comprehensive search of the English-language literature was conducted across multiple databases, including PubMed, Embase, Scopus, the Cochrane Library, and Web of Science. Eligibility was limited to retrospective case series and observational studies reporting sufficient data to directly correlate individual patients’ cTNM and pTNM classifications. Results: Thirty-one studies comprising 7939 patients met the inclusion criteria. The overall concordance rate between cT and pT was approximately 86.43%. The concordance rates between cT and pT were 82.41%, 82.03%, 78.14%, and 89.64% for cT1, cT2, cT3, and cT4, respectively. Most discordant cases in cT2 and cT3 involved understaging at clinical diagnosis. Conclusions: The limited accuracy of clinical staging in reflecting the true extent of disease remains a critical challenge in the management of LSCC. The inability of current imaging techniques to reliably detect the subtle invasion of key anatomical structures contributes to both under- and overstaging, with significant clinical implications. For patients undergoing non-surgical organ-preservation strategies, these inaccuracies may adversely affect oncologic outcomes. Full article
(This article belongs to the Section Cancer Causes, Screening and Diagnosis)
Show Figures

Figure 1

Figure 1
<p>PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow chart of studies included in systematic review and pooled analysis. The review of the English literature was performed through PubMed, Embase, Scopus, Cochrane Library, and Web of Science, accessed on 31 October 2024.</p>
Full article ">
11 pages, 1286 KiB  
Article
Discharge Against Medical Advice in Cancer Patients: Insights from a Multicenter Study in Germany
by Sarah Krieg, Sven H. Loosen, Christoph Roderburg, Andreas Krieg and Karel Kostev
Cancers 2025, 17(1), 56; https://doi.org/10.3390/cancers17010056 - 28 Dec 2024
Viewed by 578
Abstract
Background: Discharge against medical advice (DAMA) disrupts continuity of care and is associated with increased readmission rates, morbidity, and mortality. While extensively studied in general hospital populations, its prevalence and associated factors in cancer patients, where treatment adherence is critical for outcomes, remain [...] Read more.
Background: Discharge against medical advice (DAMA) disrupts continuity of care and is associated with increased readmission rates, morbidity, and mortality. While extensively studied in general hospital populations, its prevalence and associated factors in cancer patients, where treatment adherence is critical for outcomes, remain underexplored. Methods: This multicenter, cross-sectional study analyzed anonymized data from the IQVIA hospital database, including cancer patients hospitalized in 36 German hospitals between January 2019 and December 2023. Multivariate logistic regression assessed associations between DAMA and factors such as age, sex, cancer type, metastases, and comorbidities. Results: Among 51,505 cancer patients, DAMA occurred in 0.9% of hospitalizations. The highest rates were observed in cancers of the lip, oral cavity, and pharynx (2.1%), larynx (2.0%), and liver (1.8%). DAMA was more frequent in younger patients (≤50 years) (OR: 1.73; 95% CI: 1.30–2.14) and males (OR: 1.46; 95% CI: 1.23–1.72). Distant metastases showed no significant association (OR: 0.96; 95% CI: 0.81–1.13). Conclusions: The findings suggest that DAMA in cancer patients is more strongly associated with demographic and social factors than with disease severity. These results provide a basis for exploring strategies that address underlying psychosocial and economic challenges during hospitalization, particularly in younger and male patients. Further research is needed to better understand these associations and their implications for clinical practice. Full article
(This article belongs to the Special Issue Advances in Morbidity and Mortality of Cancers)
Show Figures

Figure 1

Figure 1
<p>Selection of the study sample.</p>
Full article ">Figure 2
<p>Discharge against medical advice in patients hospitalized for cancer by age and sex.</p>
Full article ">Figure 3
<p>Discharge against medical advice in patients hospitalized for cancer by cancer type.</p>
Full article ">
15 pages, 7500 KiB  
Article
The Comparative Effect of Morphine on Proliferation of Cancer Cell Lines Originating from Different Organs: An In Vitro Study
by Lydia Whitham, Mahdi Sheikh, Markus W. Hollmann and Marie-Odile Parat
Pharmaceuticals 2024, 17(12), 1656; https://doi.org/10.3390/ph17121656 - 9 Dec 2024
Viewed by 706
Abstract
Background/Objectives: Opium consumption was recently classified by the International Agency for Research on Cancer (IARC) monograph as carcinogenic to humans based on strong evidence for cancers of the larynx, lung, and urinary bladder, and limited evidence for cancers of the oesophagus, stomach, [...] Read more.
Background/Objectives: Opium consumption was recently classified by the International Agency for Research on Cancer (IARC) monograph as carcinogenic to humans based on strong evidence for cancers of the larynx, lung, and urinary bladder, and limited evidence for cancers of the oesophagus, stomach, pancreas, and pharynx. This poses the question of a potential pro-cancer effect of pharmaceutical opioid analgesics. In vitro studies employing a variety of experimental conditions suggest that opioid alkaloids have proliferative or antiproliferative effects. We set out to reconcile this discrepancy and explore the hypothesis that opioids promote cancer cell proliferation in an organ-dependent fashion. Methods: Using strictly controlled conditions, we tested the effect of morphine on the proliferation of a series of human cancer cell lines isolated from organs where cancer risk was linked causally to opium consumption in human studies (i.e., lung, bladder, and larynx), or control organs where no link between cancer risk and opium consumption has been reported in human studies (i.e., breast, colon, prostate). Results: Our results showed a minimal effect on proliferation on any cell line and no trend supporting an organ-specific effect of morphine. Conclusions: This argues against a direct effect of opioids on tumour cell proliferation to support their organ-specific effect. Full article
(This article belongs to the Special Issue Pharmacology and Toxicology of Opioids)
Show Figures

Graphical abstract

Graphical abstract
Full article ">Figure 1
<p>Proliferation of lung cancer cell lines (A-549, H1299, H1975, and H460) in response to morphine. Cells were exposed to indicated concentrations of morphine or serum for 48 h. Resazurin reduction was quantified after 4 h by fluorescence at an excitation of 560 nm and an emission of 590 nm. Results are expressed as a percentage of the viability of control cells unexposed to morphine or serum. Data are shown as mean ± SEM, n = 3 independent experiments. ns, not significant; *** <span class="html-italic">p</span> &lt; 0.001; **** <span class="html-italic">p</span> &lt; 0.0001.</p>
Full article ">Figure 2
<p>Proliferation of bladder cancer cell lines (HT-1376, T24, and UM-UC-3) in response to morphine. Cells were exposed to indicated concentrations of morphine or serum for 48 h. Resazurin reduction was quantified after 4 h by fluorescence at an excitation of 560 nm and an emission of 590 nm. Results are expressed as a percentage of the viability of control cells unexposed to morphine or serum. Data are shown as mean ± SEM, n = 3 independent experiments. ns, not significant; *** <span class="html-italic">p</span> &lt; 0.001; **** <span class="html-italic">p</span> &lt; 0.0001.</p>
Full article ">Figure 3
<p>Proliferation of pancreas cancer cell lines (AsPC-1, BxPC-3, Capan-2, and MIA PaCa-2) in response to morphine. Cells were exposed to indicated concentrations of morphine or serum for 48 h. Resazurin reduction was quantified after 4 h by fluorescence at an excitation of 560 nm and an emission of 590 nm. Results are expressed as a percentage of the viability of control cells unexposed to morphine or serum. Data are shown as mean ± SEM, n = 3 independent experiments. ns, not significant; * <span class="html-italic">p</span> &lt; 0.05; ** <span class="html-italic">p</span> &lt; 0.01; *** <span class="html-italic">p</span> &lt; 0.001; **** <span class="html-italic">p</span> &lt; 0.0001.</p>
Full article ">Figure 4
<p>Proliferation of breast cancer cell lines (MCF-7, MDA-MB-231, and MDA-MB-468) in response to morphine. Cells were exposed to indicated concentrations of morphine or serum for 48 h. Resazurin reduction was quantified after 4 h by fluorescence at an excitation of 560 nm and an emission of 590 nm. Results are expressed as a percentage of the viability of control cells unexposed to morphine or serum. Data are shown as mean ± SEM, n = 3 independent experiments. ns, not significant; *** <span class="html-italic">p</span> &lt; 0.001; **** <span class="html-italic">p</span> &lt; 0.0001.</p>
Full article ">Figure 5
<p>Proliferation of prostate cancer cell lines (22Rv1, DU145, and LNCaP) in response to morphine. Cells were exposed to indicated concentrations of morphine or serum for 48 h. Resazurin reduction was quantified after 4 h by fluorescence at an excitation of 560 nm and an emission of 590 nm. Results are expressed as a percentage of the viability of control cells unexposed to morphine or serum. Data are shown as mean ± SEM, n = 3 independent experiments. ns, not significant; * <span class="html-italic">p</span> &lt; 0.05; ** <span class="html-italic">p</span> &lt; 0.01; *** <span class="html-italic">p</span> &lt; 0.001; **** <span class="html-italic">p</span> &lt; 0.0001.</p>
Full article ">Figure 6
<p>Proliferation of colon cancer cell lines (Caco-2, HCT 116, and SW620) in response to morphine. Cells were exposed to indicated concentrations of morphine or serum for 48 h. Resazurin reduction was quantified after 4 h by fluorescence at an excitation of 560 nm and an emission of 590 nm. Results are expressed as a percentage of the viability of control cells unexposed to morphine or serum. Data are shown as mean ± SEM, n = 3 independent experiments. ns, not significant; * <span class="html-italic">p</span> &lt; 0.05; *** <span class="html-italic">p</span> &lt; 0.001; **** <span class="html-italic">p</span> &lt; 0.0001.</p>
Full article ">Figure A1
<p>Proliferation of lung cancer cell lines (A-549, H1299, H1975, and H460) in response to morphine. Cells were exposed to indicated concentrations of morphine or serum for 48 h. Resazurin reduction was quantified after 4, 6, and 8 h by fluorescence at an excitation of 560 nm and an emission of 590 nm. Results are expressed as a percentage of the viability of control cells unexposed to morphine or serum at time = 4 h. Data are shown as mean ± SEM, n = 3 independent experiments.</p>
Full article ">Figure A2
<p>Proliferation of bladder cancer cell lines (HT-3376, T24, and UM-UC-3) in response to morphine. Cells were exposed to indicated concentrations of morphine or serum for 48 h. Resazurin reduction was quantified after 4, 6, and 8 h by fluorescence at an excitation of 560 nm and an emission of 590 nm. Results are expressed as a percentage of the viability of control cells unexposed to morphine or serum at time = 4 h. Data are shown as mean ± SEM, n = 3 independent experiments.</p>
Full article ">Figure A3
<p>Proliferation of pancreas cancer cell lines (AsPC-1, BxPC-3, Capan-2, and MIA PaCa-2) in response to morphine. Cells were exposed to indicated concentrations of morphine or serum for 48 h. Resazurin reduction was quantified after 4, 6, and 8 h by fluorescence at an excitation of 560 nm and an emission of 590 nm. Results are expressed as a percentage of the viability of control cells unexposed to morphine or serum at time = 4 h. Data are shown as mean ± SEM, n = 3 independent experiments.</p>
Full article ">Figure A4
<p>Proliferation of breast cancer cell lines (MCF-7, MDA-MB-231, and MDA-MB-468) in response to morphine. Cells were exposed to indicated concentrations of morphine or serum for 48 h. Resazurin reduction was quantified after 4, 6, and 8 h by fluorescence at an excitation of 560 nm and an emission of 590 nm. Results are expressed as a percentage of the viability of control cells unexposed to morphine or serum at time = 4 h. Data are shown as mean ± SEM, n = 3 independent experiments.</p>
Full article ">Figure A5
<p>Proliferation of prostate cancer cell lines (22Rv1, DU145, and LNCaP) in response to morphine. Cells were exposed to indicated concentrations of morphine or serum for 48 h. Resazurin reduction was quantified after 4, 6, and 8 h by fluorescence at an excitation of 560 nm and an emission of 590 nm. Results are expressed as a percentage of the viability of control cells unexposed to morphine or serum at time = 4 h. Data are shown as mean ± SEM, n = 3 independent experiments.</p>
Full article ">Figure A6
<p>Proliferation of colon cancer cell lines (Caco-2, HCT 116, and SW620) in response to morphine. Cells were exposed to indicated concentrations of morphine or serum for 48 h. Resazurin reduction was quantified after 4, 6, and 8 h by fluorescence at an excitation of 560 nm and an emission of 590 nm. Results are expressed as a percentage of the viability of control cells unexposed to morphine or serum at time = 4 h. Data are shown as mean ± SEM, n = 3 independent experiments.</p>
Full article ">Figure A7
<p>Gene expression of mu (<b>left</b>), delta (<b>centre</b>), and kappa (<b>right</b>) opioid receptors expressed in transcripts per million (TPM), taken from the PCTA.</p>
Full article ">
13 pages, 573 KiB  
Article
Oncological and Functional Outcomes After Type III Cordectomy for Early Glottic Cancer (Tis, T1a): A Retrospective Study Based on Our 10-Year Experience
by Eleonora Lovati, Elisabetta Genovese, Livio Presutti, Marco Trebbi, Luca Pingani, Gian Maria Galeazzi, Maria Pia Luppi, Matteo Alicandri-Ciufelli, Daniele Marchioni and Maria Consolazione Guarnaccia
J. Clin. Med. 2024, 13(23), 7164; https://doi.org/10.3390/jcm13237164 - 26 Nov 2024
Viewed by 524
Abstract
Background: The recommended treatment for early glottic cancer is trans-oral laser microsurgery, with excellent oncological and functional outcomes. The aim of this study is to evaluate oncological and functional outcomes in patients who underwent monolateral type III laser cordectomy for early glottic cancer. [...] Read more.
Background: The recommended treatment for early glottic cancer is trans-oral laser microsurgery, with excellent oncological and functional outcomes. The aim of this study is to evaluate oncological and functional outcomes in patients who underwent monolateral type III laser cordectomy for early glottic cancer. Methods: A total of 104 patients were enrolled. Staging, histological type, grading, assessment of surgical margins, mean time of relapse, OS, DFS, and DSS were obtained. Maximum phonation time, GIRBAS score, shimmer, jitter, fundamental frequency, and Yanagihara score were evaluated. Patients were submitted to the VHI-10 questionnaire. Results: Correlations between patients with single recurrence and the anterior commissure involvement were analyzed, as well as correlations between patients with recurrence and the status of margins. Correlations between VHI-10 scores and anterior commissure involvement were analyzed. Conclusions: The recurrence rate was higher in patients with anterior commissure involvement. A significant inversely proportional association between DSS and assessment of surgical margins was observed. The distribution of VHI-10 scores differed significatively in patients with and without anterior commissure involvement. Vocal results reflected mild dysphonia. Full article
(This article belongs to the Section Otolaryngology)
Show Figures

Figure 1

Figure 1
<p>Differences in distribution of patients with a single recurrence and the distribution of patients who underwent extended resection to anterior commissure.</p>
Full article ">Figure 2
<p>Mean values of GIRBAS parameters.</p>
Full article ">
16 pages, 495 KiB  
Article
The Influence of the Microbiome on the Complications of Radiotherapy and Its Effectiveness in Patients with Laryngeal Cancer
by Karolina Dorobisz, Tadeusz Dorobisz, Katarzyna Pazdro-Zastawny, Katarzyna Czyż and Marzena Janczak
Cancers 2024, 16(21), 3707; https://doi.org/10.3390/cancers16213707 - 1 Nov 2024
Viewed by 934
Abstract
Introduction: Radiotherapy is an effective method of treating cancer and affects 50% of patients. Intensity-modulated radiotherapy (IMRT) is a modernized method of classical radiation used in the treatment of laryngeal cancer. Treatment with intent to preserve the larynx is not always safe or [...] Read more.
Introduction: Radiotherapy is an effective method of treating cancer and affects 50% of patients. Intensity-modulated radiotherapy (IMRT) is a modernized method of classical radiation used in the treatment of laryngeal cancer. Treatment with intent to preserve the larynx is not always safe or complication-free. The microbiome may significantly influence the effectiveness of oncological treatment, especially radiotherapy, and may also be modified by the toxic response to radiation. Objective: The aim of the study was to prospectively assess the microbiome and its influence on radiotherapy toxicity in patients with laryngeal cancer. Results: Statistically significant risk factors for complications after radiotherapy were the percentage of Porphyromonas of at least 6.7%, the percentage of Fusobacterium of at least 2.6% and the percentage of Catonella of at least 2.6%. Conclusions: The importance of the microbiome in oncology has been confirmed in many studies. Effective radiotherapy treatment and the prevention of radiation-induced oral mucositis is a challenge in oncology. The microbiome may be an important part of personalized cancer treatment. The assessment of the microbiome of patients diagnosed with cancer may provide the opportunity to predict the response to treatment and its effectiveness. The influence of the microbiome may be important in predicting the risk group for radiotherapy treatment failure. The possibility of modifying the microbiome may become a goal to improve the prognosis of patients with laryngeal cancer. Fusobacterium, Porphyromonas and Catonella are important risk factors for radiation-induced oral mucositis in patients with laryngeal cancer. Full article
(This article belongs to the Section Tumor Microenvironment)
Show Figures

Figure 1

Figure 1
<p>The percentage of bacteria of the genus <span class="html-italic">Gemella</span>, <span class="html-italic">Porphyromonas</span>, <span class="html-italic">Fusobacterium</span> and <span class="html-italic">Catonella</span> in the group of patients with and without complications after radiotherapy and the results of the significance test. Red color means that the difference is statistically significant.</p>
Full article ">
16 pages, 925 KiB  
Article
Analysis of Risk Factors with Assessment of the Impact of the Microbiome on the Risk of Squamous Cell Carcinoma of the Larynx
by Karolina Dorobisz, Tadeusz Dorobisz and Katarzyna Pazdro-Zastawny
J. Clin. Med. 2024, 13(20), 6101; https://doi.org/10.3390/jcm13206101 - 13 Oct 2024
Cited by 1 | Viewed by 1077
Abstract
Introduction: Head and neck squamous cell carcinoma (HNSCC) ranks sixth among cancers in the world, and the 5-year survival rate ranges from 25% to 60%. The risk factors for HNSCC are primarily smoking, alcohol consumption and human papillomavirus (HPV). Data indicate that [...] Read more.
Introduction: Head and neck squamous cell carcinoma (HNSCC) ranks sixth among cancers in the world, and the 5-year survival rate ranges from 25% to 60%. The risk factors for HNSCC are primarily smoking, alcohol consumption and human papillomavirus (HPV). Data indicate that 15–20% of cancers are caused by infectious agents, 20–30% by smoking and 30–35% by unhealthy lifestyles, diet, lack of physical activity and obesity. Dysbiosis is a microbiome imbalance, which promotes oncogenesis by intensifying inflammatory processes and affecting the host’s metabolism. Profiling the microbiome in various types of cancer is currently the subject of research and analysis. However, there is still little information on the correlation of the microbiome with HNSCC and its impact on oncogenesis, the course of the disease and its treatment. Objective: The aim of the study was to prospectively assess risk factors with assessment of the impact of the microbiome on the risk of squamous cell carcinoma of the larynx. The study included a group of 44 patients diagnosed with squamous cell carcinoma of the larynx and 30 patients from the control group. Results: In the control group, bacteria of the normal microbiome dominated—the genus Streptococcus, Gemella, Neisseria and Kingella. In the group of patients with laryngeal cancer, Prevotella, Clostridiales and Stomatobaculum were found significantly more often. Porphyromonas, Fusobacterium, Lactobacillus, Actinobacteria, Actinomyces and Shaalia odontolytica were also found at a higher percentage in the study group. Analyzing the phylum, Firmicutes dominated in the control group; there were statistically significantly more of them than in patients from the study group. Bacteroides and Bacillota were found significantly more often in patients with laryngeal cancer. Conclusions: The importance of the microbiome in oncology has been confirmed in many studies. Independent risk factors for laryngeal cancer were primarily a lower number of Firmicutes in the microbiome, but also an increased leukocyte level above 6.52 × 103/mm and a decreased total protein level below 6.9 g/dL. Prevotella, Clostridiales, Stomatobaculum, Porphyromonas, Fusobacterium, Lactobacillus, Actinobacteria, Actinomyces and Shaalia were considered to be the bacteria contributing to the development of laryngeal cancer. Streptococcus, Gemella, Neisserie and Kingella were considered to be protective bacteria. Moreover, the study confirmed the significant impact of smoking, alcohol consumption and poor oral hygiene on the development of laryngeal cancer. The microbiome, its identification and manipulation may constitute a breakthrough discovery for improving the diagnosis and oncological therapy of laryngeal cancer, and also of the entire group of HNSCC. Profiling the microbiome may allow for personalized therapy related to its modification. Assessing the microbiome of patients diagnosed with cancer may provide an opportunity to predict treatment response and effectiveness. Full article
(This article belongs to the Section Oncology)
Show Figures

Figure 1

Figure 1
<p>Microbiome of the study and control groups.</p>
Full article ">Figure 2
<p>ROC curve for estimating the probability of the presence of head and neck cancer based on a logit model taking into account the number of leukocytes, total protein concentration and the percentage of bacteria from the Firmicutes phylum in the microbiota. Cut-off value and area under the curve.</p>
Full article ">
11 pages, 2970 KiB  
Article
Chest Tube Placement of Secondary Tracheoesophageal Voice Prosthesis: Overcoming Challenging Anatomy in the Laryngectomy Patient
by Courtney B. Shires, Joseph S. Schertzer, Lauren Ottenstein, Tricia Harris and Merry E. Sebelik
J. Pers. Med. 2024, 14(10), 1021; https://doi.org/10.3390/jpm14101021 - 24 Sep 2024
Viewed by 996
Abstract
Introduction: Total laryngectomy is used to cure advanced larynx cancer in many patients. The removal of the larynx requires the rehabilitation of the patient’s ability to communicate, and one common method is to place a tracheoesophageal voice prosthesis (TEP) as a secondary procedure [...] Read more.
Introduction: Total laryngectomy is used to cure advanced larynx cancer in many patients. The removal of the larynx requires the rehabilitation of the patient’s ability to communicate, and one common method is to place a tracheoesophageal voice prosthesis (TEP) as a secondary procedure after the patient has completed cancer treatment. The traditional technique utilizes a rigid esophagoscope for access, but this can prove difficult in many patients who have kyphosis, scarring of the neck, or trismus. We describe a technique to allow TEP placement in these challenging patients that does not utilize rigid esophagoscopy to access the tracheoesophageal puncture site. Methods: For more than 15 years, the senior authors of this study have used this technique in patients in whom traditional methods of TEP with rigid esophagoscope were unsuccessful or not attempted due to the anticipated high probability of failure. The ease of this technique has prompted its use for all patients undergoing secondary TEP placement in their practice. The technique is described in detail in the Methods section below. Results: The described method has been successfully utilized to place TEPs in many patients with challenging anatomy. There have been no failed placements, including a patient with severe trismus who was able to have a TEP placed by placing the chest tube and flexible endoscope transnasally. Further, because of precise visualization and ease of the technique, there have been no observed complications of injury to the pharyngoesophageal lumen or creation of a false passage. Conclusion: The use of a chest tube and flexible scope allows for the protection of the pharyngoesophageal lumen, precise visualization and placement of the puncture, and avoidance of a false tracheoesophageal passage, all while minimizing the need for extension of the patient’s neck. This has proven ideal for patients suffering the consequences of cancer treatment such as cervical scarring, fibrosis, kyphosis, and trismus. Full article
(This article belongs to the Section Personalized Therapy and Drug Delivery)
Show Figures

Figure 1

Figure 1
<p>The tapered end of the chest tube is cut (red line) and the fenestrated end (orange arrow) is inserted into the mouth.</p>
Full article ">Figure 2
<p>The fenestrated end is advanced into the esophagus. The cut tapered end is external and provides an opening for scope insertion. As seen here, the chest tube can be placed with limited neck extension. The length protruding from the mouth need only be long enough to maintain control of it while passing the flexible endoscope.</p>
Full article ">Figure 3
<p>The surgeon and endoscopist work together to place the trocar through the fenestration in the anterior wall of the chest tube under endoscopic view.</p>
Full article ">Figure 4
<p>A fenestration in the chest tube is advanced until it is underlying the desired puncture site. Appropriate positioning can be confirmed by palpating in the fenestration with a hemostat.</p>
Full article ">Figure 5
<p>Demonstration of the trocar insertion technique. The chest tube is the ideal adjunct for trocar insertion as it is flexible, provides an opening for insertion, and protects the esophagus posteriorly.</p>
Full article ">Figure 6
<p>Insertion of trocar under endoscopic visualization. The chest tube protects the posterior esophageal wall from injury.</p>
Full article ">Figure 7
<p>The guidewire can be advanced cranially under endoscopic visualization.</p>
Full article ">
13 pages, 15027 KiB  
Article
The Solute Carrier (SLC) Transporter Superfamily as Therapeutic Targets for the Treatment of Head and Neck Squamous Cell Carcinoma
by Sang Yeon Cho and Nam Sook Kang
Cancers 2024, 16(18), 3226; https://doi.org/10.3390/cancers16183226 - 22 Sep 2024
Cited by 1 | Viewed by 1508
Abstract
Background: Head and neck squamous cell carcinoma (HNSC) is the most prevalent cancer in the head and neck region, originating from the mucosal epithelium of the oral cavity, pharynx, and larynx. The solute carrier (SLC) transporter superfamily, consisting of over 400 proteins [...] Read more.
Background: Head and neck squamous cell carcinoma (HNSC) is the most prevalent cancer in the head and neck region, originating from the mucosal epithelium of the oral cavity, pharynx, and larynx. The solute carrier (SLC) transporter superfamily, consisting of over 400 proteins across 65 families, plays a crucial role in cellular functions and presents promising targets in precision oncology. This study aims to analyze the expression of SLC transporters in HNSC and their potential as biomarkers and therapeutic targets. Methods: We leveraged mRNA and protein expression data from The Cancer Genome Atlas (TCGA) and The Human Protein Atlas (HPA) to examine SLC transporter expression in HNSC. Gene Set Enrichment Analysis (GSEA) was conducted to assess the involvement of SLC transporters in various oncogenic pathways. Results: Significant upregulation of SLC transporters was observed in tumor tissues compared to normal tissues, with notable increases in SLC16A3, SLC53A1, SLC25A32, and SLC2A3. This upregulation correlated with poorer overall survival (OS) and disease-specific survival (DSS). GSEA revealed that these transporters are significantly involved in critical oncogenic pathways, including epithelial-mesenchymal transition (EMT), angiogenesis, and hypoxia, which are vital for cancer progression and metastasis. Conclusions: The study identifies SLC transporters as potential biomarkers and therapeutic targets in HNSC. Targeting these transporters with small molecule inhibitors could disrupt essential supply routes for cancer cells, enhancing treatment efficacy and improving patient outcomes. This study paves the way for developing SLC-based target therapies in precision oncology, with the goal of improving survival rates for patients with HNSC. Full article
(This article belongs to the Section Molecular Cancer Biology)
Show Figures

Figure 1

Figure 1
<p>Differential expression of SLC superfamily genes in normal and tumor tissues. (<b>A</b>) The dot plot depicting the RNA-seq expression levels of 446 SLC superfamily in normal (<b>left panel</b>, green circles) and tumor tissues (<b>right panel</b>, red circles). The size of the circles corresponds to the RNA-seq expression levels, with larger circles indicating a higher expression. Significant changes in expression between normal and tumor tissues are indicated by the color intensity and size of the circles. (<b>B</b>) The list enumerates the 65 SLC families, providing the name for the specific SLC families analyzed and their corresponding SLC numbers.</p>
Full article ">Figure 2
<p>Prognostic significance of SLC genes in cancer. (<b>A</b>) Volcano plot showing the association between SLC gene expression and overall survival. (<b>B</b>) Volcano plot displaying the association between SLC gene expression and disease-specific survival. The x-axis represents the Cox regression hazard ratio, and the y-axis shows the –log10(<span class="html-italic">p</span>-value). Blue circles indicate SLC genes significantly associated with better survival, while red circles indicate those associated with worse survival.</p>
Full article ">Figure 3
<p>Classification and protein expression of SLC targets in HNSC. (<b>A</b>) The Chord diagram shows the protein levels detected in tumor (outer arc) and normal tissues (inner arc), with the expression levels indicated by color: high (dark purple), medium (red), low (orange), not detected (yellow), and non-available (grey). (<b>B</b>) The y-axis represents the patient proportions, while the x-axis lists the specific SLC proteins analyzed. The color bars represent the levels of protein expression detected in each cell type. Bar chart depicting the proportion of patients with high (dark purple), medium (red), low (orange), and not detected (yellow) expression levels of selected SLC proteins in HNSC. Bar chart depicting the protein level of SLC targets with high (dark blue), medium (blue), low (light blue), and not detected (very light blue) expression levels of selected SLC proteins in normal head and neck cells.</p>
Full article ">Figure 4
<p>Expression, genetic alteration, and prognostic significance of selected SLC genes in cancer. (<b>A</b>) Box plots representing log2 expression levels of SLC16A3, SLC53A1, SLC25A32, and SLC2A3 in normal (green) versus cancer (red) tissues. Immunohistochemistry staining confirms high expression level and cell membrane localization in cancer tissues. Scale bars: 50 μm. (<b>B</b>) Genetic alteration frequencies of selected SLC genes. Kaplan-Meier plots showing overall survival and disease-specific survival for patients with altered (red) versus unaltered (blue) SLC genes. Statistical significance determined by log-rank test. (<b>C</b>) Predicted 3D structures of SLC proteins generated using AlphaFold2, color-coded by the predicted local distance difference test (pLDDT) scores: very high confidence (blue, pLDDT &gt; 90), high confidence (light blue, 70 &lt; pLDDT ≤ 90), low confidence (yellow, 50 &lt; pLDDT ≤ 70), and very low confidence (red, pLDDT ≤ 50). Specific amino acid mutations were classified using AlphaMissense that categorizes missense mutations as likely pathogenic, likely benign, or uncertain based on evolutionary constraints and protein structure context. These mutations are mapped onto the structures, highlighting potential functional disruptions. (<b>D</b>) Kaplan-Meier survival curves illustrating the prognostic significance of high (red) versus low (black) expression levels of SLC genes for overall survival and disease-specific survival. Hazard ratios (HR) and <span class="html-italic">p</span>-values are provided.</p>
Full article ">Figure 5
<p>Gene Set Enrichment Analysis (GSEA) of selected SLC targets in HNSC. Heatmaps and enrichment plots of pathways significantly enriched in cancers with high expression of SLC16A3, SLC53A1, SLC25A32, and SLC2A3. Each panel shows the top pathways with their corresponding normalized enrichment scores (NES) and nominal <span class="html-italic">p</span>-values. The heatmaps illustrate the expression levels of key genes within each pathway, with samples ordered by their expression levels of the respective SLC gene. For each gene, the rank in the gene list and the corresponding running enrichment score (ES) are provided.</p>
Full article ">
10 pages, 2037 KiB  
Systematic Review
A Systematic Review Evaluating the Diagnostic Efficacy of Narrow-Band Imaging for Laryngeal Cancer Detection
by Ileana Alexandra Sanda, Razvan Hainarosie, Irina Gabriela Ionita, Catalina Voiosu, Marius Razvan Ristea and Adina Zamfir Chiru Anton
Medicina 2024, 60(8), 1205; https://doi.org/10.3390/medicina60081205 - 25 Jul 2024
Viewed by 1263
Abstract
Background: Narrow-band imaging is an advanced endoscopic technology used to detect changes on the laryngeal tissue surface, employing a comparative approach alongside white-light endoscopy to facilitate histopathological examination. Objective: This study aimed to assess the utility and advantages of NBI (narrow-band [...] Read more.
Background: Narrow-band imaging is an advanced endoscopic technology used to detect changes on the laryngeal tissue surface, employing a comparative approach alongside white-light endoscopy to facilitate histopathological examination. Objective: This study aimed to assess the utility and advantages of NBI (narrow-band imaging) in identifying malignant laryngeal lesions through a comparative analysis with histopathological examination. Methods: We conducted a systematic literature review, utilizing databases such as PubMed, the CNKI database, and Embase for our research. Results: We analyzed the articles by reviewing their titles and abstracts, selecting those we considered relevant based on determined criteria; in the final phase, we examined the relevant studies according to the specific eligibility criteria. Conclusions: Narrow-band imaging is an advanced endoscopic technology that demonstrates its efficacy as a tool for diagnosing malignant laryngeal lesions and comparing them to premalignant lesions. The European Society of Laryngology has implemented a standardized classification system for laryngeal lesions to enhance data correlation and organization. Full article
(This article belongs to the Special Issue Developments and Innovations in Head and Neck Surgery)
Show Figures

Figure 1

Figure 1
<p>Evaluation of methodological quality using Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) framework.</p>
Full article ">Figure 2
<p>Evaluation of methodological quality using QUADAS-2 framework—percentage.</p>
Full article ">Figure 3
<p>A flow chart of the article selection process.</p>
Full article ">Figure 4
<p>Forest plot for <span class="html-italic">specificity</span> of NBI [<a href="#B22-medicina-60-01205" class="html-bibr">22</a>,<a href="#B23-medicina-60-01205" class="html-bibr">23</a>,<a href="#B24-medicina-60-01205" class="html-bibr">24</a>,<a href="#B25-medicina-60-01205" class="html-bibr">25</a>,<a href="#B26-medicina-60-01205" class="html-bibr">26</a>,<a href="#B27-medicina-60-01205" class="html-bibr">27</a>,<a href="#B28-medicina-60-01205" class="html-bibr">28</a>,<a href="#B29-medicina-60-01205" class="html-bibr">29</a>,<a href="#B30-medicina-60-01205" class="html-bibr">30</a>,<a href="#B31-medicina-60-01205" class="html-bibr">31</a>,<a href="#B32-medicina-60-01205" class="html-bibr">32</a>,<a href="#B33-medicina-60-01205" class="html-bibr">33</a>,<a href="#B34-medicina-60-01205" class="html-bibr">34</a>,<a href="#B35-medicina-60-01205" class="html-bibr">35</a>,<a href="#B36-medicina-60-01205" class="html-bibr">36</a>,<a href="#B37-medicina-60-01205" class="html-bibr">37</a>,<a href="#B38-medicina-60-01205" class="html-bibr">38</a>].</p>
Full article ">Figure 5
<p>Forest plot for sensitivity of NBI [<a href="#B23-medicina-60-01205" class="html-bibr">23</a>,<a href="#B24-medicina-60-01205" class="html-bibr">24</a>,<a href="#B25-medicina-60-01205" class="html-bibr">25</a>,<a href="#B27-medicina-60-01205" class="html-bibr">27</a>,<a href="#B28-medicina-60-01205" class="html-bibr">28</a>,<a href="#B29-medicina-60-01205" class="html-bibr">29</a>,<a href="#B34-medicina-60-01205" class="html-bibr">34</a>,<a href="#B35-medicina-60-01205" class="html-bibr">35</a>,<a href="#B37-medicina-60-01205" class="html-bibr">37</a>].</p>
Full article ">
16 pages, 623 KiB  
Review
The Role of Oncogenic Viruses in Head and Neck Cancers: Epidemiology, Pathogenesis, and Advancements in Detection Methods
by Pinelopi Samara, Michail Athanasopoulos, Stylianos Mastronikolis, Efthymios Kyrodimos, Ioannis Athanasopoulos and Nicholas S. Mastronikolis
Microorganisms 2024, 12(7), 1482; https://doi.org/10.3390/microorganisms12071482 - 19 Jul 2024
Cited by 2 | Viewed by 2128
Abstract
Head and neck cancers (HNCs) constitute a wide range of malignancies originating from the epithelial lining of the upper aerodigestive tract, including the oral cavity, pharynx, larynx, nasal cavity, paranasal sinuses, and salivary glands. Although lymphomas affecting this region are not conventionally classified [...] Read more.
Head and neck cancers (HNCs) constitute a wide range of malignancies originating from the epithelial lining of the upper aerodigestive tract, including the oral cavity, pharynx, larynx, nasal cavity, paranasal sinuses, and salivary glands. Although lymphomas affecting this region are not conventionally classified as HNCs, they may occur in lymph nodes or mucosa-associated lymphoid tissues within the head and neck. Oncogenic viruses play a crucial role in HNC onset. Human papillomavirus (HPV) is extensively studied for its association with oropharyngeal cancers; nevertheless, other oncogenic viruses also contribute to HNC development. This review provides an overview of the epidemiology, pathogenesis, and advancements in detection methods of oncogenic viruses associated with HNCs, recognizing HPV’s well-established role while exploring additional viral connections. Notably, Epstein–Barr virus is linked to nasopharyngeal carcinoma and lymphomas. Human herpesvirus 8 is implicated in Kaposi’s sarcoma, and Merkel cell polyomavirus is associated with subsets of HNCs. Additionally, hepatitis viruses are examined for their potential association with HNCs. Understanding the viral contributions in the head and neck area is critical for refining therapeutic approaches. This review underlines the interaction between viruses and malignancies in this region, highlighting the necessity for ongoing research to elucidate additional mechanisms and enhance clinical outcomes. Full article
(This article belongs to the Section Medical Microbiology)
Show Figures

Figure 1

Figure 1
<p>Illustration depicting the multifactorial pathogenesis of head and neck cancer, highlighting the role of oncogenic viruses in conjunction with environmental factors (such as tobacco smoke and alcohol consumption) and genetic factors (including inherited genetic mutations). The image shows how viruses can integrate into host DNA, disrupt normal cell cycle regulation, and evade immune surveillance. These mechanisms, combined with exposure to carcinogens and genetic predispositions, lead to malignant transformation and tumor development. Created with BioRender.com (accessed on 6 July 2024).</p>
Full article ">
24 pages, 1155 KiB  
Review
The Role of Biomarkers in HPV-Positive Head and Neck Squamous Cell Carcinoma: Towards Precision Medicine
by Antea Krsek, Lara Baticic, Vlatka Sotosek and Tamara Braut
Diagnostics 2024, 14(13), 1448; https://doi.org/10.3390/diagnostics14131448 - 7 Jul 2024
Cited by 8 | Viewed by 2019
Abstract
Head and neck cancer (HNC) represents a significant global health challenge, with squamous cell carcinomas (SCCs) accounting for approximately 90% of all HNC cases. These malignancies, collectively referred to as head and neck squamous cell carcinoma (HNSCC), originate from the mucosal epithelium lining [...] Read more.
Head and neck cancer (HNC) represents a significant global health challenge, with squamous cell carcinomas (SCCs) accounting for approximately 90% of all HNC cases. These malignancies, collectively referred to as head and neck squamous cell carcinoma (HNSCC), originate from the mucosal epithelium lining the larynx, pharynx, and oral cavity. The primary risk factors associated with HNSCC in economically disadvantaged nations have been chronic alcohol consumption and tobacco use. However, in more affluent countries, the landscape of HNSCC has shifted with the identification of human papillomavirus (HPV) infection, particularly HPV-16, as a major risk factor, especially among nonsmokers. Understanding the evolving risk factors and the distinct biological behaviors of HPV-positive and HPV-negative HNSCC is critical for developing targeted treatment strategies and improving patient outcomes in this complex and diverse group of cancers. Accurate diagnosis of HPV-positive HNSCC is essential for developing a comprehensive model that integrates the molecular characteristics, immune microenvironment, and clinical outcomes. The aim of this comprehensive review was to summarize the current knowledge and advances in the identification of DNA, RNA, and protein biomarkers in bodily fluids and tissues that have introduced new possibilities for minimally or non-invasive cancer diagnosis, monitoring, and assessment of therapeutic responses. Full article
(This article belongs to the Special Issue Advances in Laboratory Markers of Human Disease)
Show Figures

Figure 1

Figure 1
<p>Risk factors for the development of head and neck squamous cell carcinoma. The image outlines the risk factors for head and neck squamous cell carcinoma (HNSCC), including alcohol and tobacco use, graft-versus-host disease, ultraviolet (UV) light, viruses, and occupational exposure. Alcohol and tobacco use are major risk factors, as they contain carcinogens that can lead to cellular mutations and cancer. Graft-versus-host disease creates a proinflammatory environment where donor immune cells attack the recipient’s tissues after an allogeneic stem cell transplant. This chronic inflammation and immune dysregulation increase the risk of secondary malignancies like HNSCC. Ultraviolet (UV) light causes direct DNA damage, leading to mutations and cancer. Viruses such as Epstein–Barr Virus (EBV) and human papillomavirus (HPV-16) are known to induce oncogenic transformations in cells, significantly raising the risk of HNSCC. Occupational exposure involves contact with carcinogenic substances in certain industries, which raises the risk of cancer development. Examples include asbestos fibers, which increase HNSCC risk, wood dust exposure in carpentry, which raises the risk of nasopharyngeal cancer, and exposure to industrial chemicals like formaldehyde and solvents in the textile, rubber, and plastic industries, as well as nickel refining and processing.</p>
Full article ">Figure 2
<p>ctDNA as a biomarker in oral and oropharyngeal squamous cell carcinoma. This figure illustrates the circulation of tumor-related materials in the bloodstream relevant to oral squamous cell carcinoma (OSCC) and head and neck squamous cell carcinoma (HNSCC). The tumor releases necrotic tumor cells, macrophages, circulating tumor cells (CTCs), and circulating tumor DNA (ctDNA) into the bloodstream, shown alongside red blood cells. Macrophages as immune cells interact with these tumor components. CTCs are live tumor cells that have shed into the bloodstream, and ctDNA consists of fragments of tumor DNA circulating in the blood. These materials represent various stages of tumor cell degradation and dissemination, with ctDNA a potential cancer detection and monitoring biomarker. The figure highlights the complexity of tumor biology and the potential for blood-based biomarkers in diagnosing and monitoring OSCC and HNSCC.</p>
Full article ">
8 pages, 963 KiB  
Article
Quantifying the Dosimetric Impact of Proton Range Uncertainties on RBE-Weighted Dose Distributions in Intensity-Modulated Proton Therapy for Bilateral Head and Neck Cancer
by Suresh Rana, Noufal Manthala Padannayil, Linh Tran, Anatoly B. Rosenfeld, Hina Saeed and Michael Kasper
Curr. Oncol. 2024, 31(7), 3690-3697; https://doi.org/10.3390/curroncol31070272 - 27 Jun 2024
Viewed by 1373
Abstract
Background: In current clinical practice, intensity-modulated proton therapy (IMPT) head and neck cancer (HNC) plans are generated using a constant relative biological effectiveness (cRBE) of 1.1. The primary goal of this study was to explore the dosimetric impact of proton range uncertainties on [...] Read more.
Background: In current clinical practice, intensity-modulated proton therapy (IMPT) head and neck cancer (HNC) plans are generated using a constant relative biological effectiveness (cRBE) of 1.1. The primary goal of this study was to explore the dosimetric impact of proton range uncertainties on RBE-weighted dose (RWD) distributions using a variable RBE (vRBE) model in the context of bilateral HNC IMPT plans. Methods: The current study included the computed tomography (CT) datasets of ten bilateral HNC patients who had undergone photon therapy. Each patient’s plan was generated using three IMPT beams to deliver doses to the CTV_High and CTV_Low for doses of 70 Gy(RBE) and 54 Gy(RBE), respectively, in 35 fractions through a simultaneous integrated boost (SIB) technique. Each nominal plan calculated with a cRBE of 1.1 was subjected to the range uncertainties of ±3%. The McNamara vRBE model was used for RWD calculations. For each patient, the differences in dosimetric metrices between the RWD and nominal dose distributions were compared. Results: The constrictor muscles, oral cavity, parotids, larynx, thyroid, and esophagus showed average differences in mean dose (Dmean) values up to 6.91 Gy(RBE), indicating the impact of proton range uncertainties on RWD distributions. Similarly, the brachial plexus, brain, brainstem, spinal cord, and mandible showed varying degrees of the average differences in maximum dose (Dmax) values (2.78–10.75 Gy(RBE)). The Dmean and Dmax to the CTV from RWD distributions were within ±2% of the dosimetric results in nominal plans. Conclusion: The consistent trend of higher mean and maximum doses to the OARs with the McNamara vRBE model compared to cRBE model highlighted the need for consideration of proton range uncertainties while evaluating OAR doses in bilateral HNC IMPT plans. Full article
Show Figures

Figure 1

Figure 1
<p>(<b>a</b>) Dose distributions (cRBE = 1.1) in a nominal plan (no range uncertainty) of an example HNC patient. (<b>b</b>) LET<sub>d</sub> distributions in a nominal plan of the same patient shown in (<b>a</b>).</p>
Full article ">Figure 2
<p>(<b>a</b>) Mean dose to the CTV_70 and (<b>b</b>) maximum dose to the CTV_70 in nominal (cRBE), RWD of nominal, RWD of +3% range uncertainty, and RWD of −3% range uncertainty plans in ten patients.</p>
Full article ">
9 pages, 1121 KiB  
Article
A New Proposal for Adequate Resection Margins in Larynx and Hypopharynx Tumor Surgery—Are the RCP Guidelines Feasible?
by Simone E. Bernard, Cornelia G. F. van Lanschot, Jose A. Hardillo, Dominiek A. Monserez, Cees A. Meeuwis, Robert J. Baatenburg de Jong, Senada Koljenović and Aniel Sewnaik
Cancers 2024, 16(11), 2058; https://doi.org/10.3390/cancers16112058 - 29 May 2024
Cited by 1 | Viewed by 1515
Abstract
Background: Resection margins are an important prognostic factor for patients with head and neck cancer. In general, for head and neck surgery, a margin >5 mm is advised by the Royal College of Pathologists. However, this cannot always be achieved during laryngeal and [...] Read more.
Background: Resection margins are an important prognostic factor for patients with head and neck cancer. In general, for head and neck surgery, a margin >5 mm is advised by the Royal College of Pathologists. However, this cannot always be achieved during laryngeal and hypopharyngeal surgery. The aim of this study is to identify the resection surfaces and measure the maximum feasible margins per subsite. The clinical relevance of these maximum feasible resection margins were analyzed in this descriptive anatomical study. Methods: head and neck surgeons and a pathologist from the Erasmus MC performed a total laryngectomy and laryngopharyngectomy on a head and neck specimen specifically available for research. Results: For a total laryngectomy, resection margins >5 mm were not feasible for the ventral and dorsal resection surface. For a total laryngopharyngectomy, resection margins >5 mm were not feasible for the ventral, dorsal and lateral resection surface. Conclusion: Clear resection margins, defined as a margin >5 mm, are not always feasible in laryngeal and hypopharyngeal surgery, due to the anatomy of the larynx and tumor location. However, striving for a maximum feasible margin is still the main goal. We propose a new guideline for maximum feasible but adequate resection margins in larynx and hypopharynx tumor surgery. Full article
(This article belongs to the Special Issue Advances in Surgery of Head and Neck Squamous Cell Carcinoma)
Show Figures

Figure 1

Figure 1
<p>The resection surfaces per subsite and tumor location. (<b>A</b>) Cranial resection surface. (<b>B</b>) Ventral resection surface. (<b>C</b>) Dorsal resection surface. (<b>D</b>) Lateral resection surface. (<b>E</b>) Caudal resection surface.</p>
Full article ">
Back to TopTop